Patents by Inventor Jeffrey McKenna

Jeffrey McKenna has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMBINATION THERAPY FOR THE TREATMENT OF CANCER
    Publication number: 20220211815
    Abstract: The present disclosure relates to a pharmaceutical composition comprising a STING agonist molecule in combination with an IL-15/IL-15Ra complex. The present combination can be administered independently or separately, in a quantity which is therapeutically effective for the treatment of cancer. Also provided is the use of such a combination for the manufacture of a medicament; the use of such a combination as a medicine; a kit of parts comprising such a combination; and a method of treatment of such a combination.
    Type: Application
    Filed: February 1, 2019
    Publication date: July 7, 2022
    Inventors: Nadja KOPP, Justin LEONG, Jeffrey MCKENNA, Chudi Obioma NDUBAKU, Maria PINZON-ORTIZ, Xianhui RONG, Ryan SULLIVAN
  • COVALENT TARGETING OF E3 LIGASES
    Publication number: 20210369731
    Abstract: Disclosed herein, inter alia, are compositions and methods for targeting E3 ligases. In an aspect is a targeted protein degrader including 1) a targeted protein binder and 2) an E3 Ubiquitin ligase binder, wherein the E3 Ubiquitin ligase is human RNF4 or human RNF114. In an aspect is provided a pharmaceutical composition including a compound as described herein, including embodiments, and a pharmaceutically acceptable excipient.
    Type: Application
    Filed: October 9, 2019
    Publication date: December 2, 2021
    Inventors: Jessica Spradlin, Carl C. Ward, Daniel K. Nomura, Markus Schirle, John A. Tallarico, Jeffrey McKenna, Thomas John Maimone, Xirui Hu
  • Locked nucleic acid cyclic dinucleotide compounds and uses thereof
    Patent number: 11098077
    Abstract: The present invention provides highly active locked nucleic acid cyclic-dinucleotide (LNA-CDN) immune stimulators that activate DCs via the cytoplasmic receptor known as STING (Stimulator of Interferon Genes). In particular, the LNA-CDNs of the present invention are provided in the form of a composition comprising one or more cyclic dinucleotides that induce human STING-dependent type I interferon production, wherein the cyclic dinucleotides present in the composition have at least one 2?, 4? locked nucleic acids within the cyclic dinucleotide.
    Type: Grant
    Filed: July 1, 2017
    Date of Patent: August 24, 2021
    Assignees: CHINOOK THERAPEUTICS, INC., NOVARTIS AG
    Inventors: David Braun Kanne, Chudi Obioma Ndubaku, Jacob Robert Bruml, Thanh Ngoc Lan Le, Jeffrey McKenna, George Scott Tria, Stephen Canham
  • Bis 2?-5?-RR-(3?F-A)(3?F-A) cyclic dinucleotide compound and uses thereof
    Patent number: 10975114
    Abstract: The present invention provides the cyclic dinucleotide compound 2?2?-RR-(3?F-A)(3?F-A) as a highly active immune stimulator that activates DCs via the cytoplasmic receptor known as STING (Stimulator of Interferon Genes), and compositions and uses thereof.
    Type: Grant
    Filed: April 26, 2018
    Date of Patent: April 13, 2021
    Assignees: CHINOOK THERAPEUTICS, INC., NOVARTIS AG
    Inventors: Justin Leong, Chudi Obioma Ndubaku, Jeffrey McKenna
  • Compositions and methods for activating “stimulator of interferon gene”-dependent signalling
    Patent number: 10906930
    Abstract: The present invention provides highly active cyclic-di-nucleotide (CDN) immune stimulators that activate DCs via a recently discovered cytoplasmic receptor known as STING (Stimulator of Interferon Genes). In particular, the CDNs of the present invention are provided in the form of a composition comprising one or more cyclic purine dinucleotides induce human STING-dependent type I interferon production, wherein the cyclic purine dinucleotides present in the composition are 2?- or 3?-mono-fluoro substituted, or 2?3?-di-fluoro substituted mixed linkage 2?,5?-3?,5? CDNs.
    Type: Grant
    Filed: October 28, 2016
    Date of Patent: February 2, 2021
    Assignees: CHINOOK THERAPEUTICS, INC., NOVARTIS AG
    Inventors: George Edwin Katibah, David Kanne, Leonard Sung, Kelsey Gauthier, Laura Hix Glickman, Justin Leong, Sarah M. McWhirter, Thomas W. Dubensky, Jr., Jeffrey McKenna, Stephen M. Canham, Chudi Obioma Ndubaku
  • BIS 2'-5'-RR-(3'F-A)(3'F-A) CYCLIC DINUCLEOTIDE COMPOUND AND USES THEREOF
    Publication number: 20200199169
    Abstract: The present invention provides the cyclic dinucleotide compound 2?2?-RR-(3?F-A)(3?F-A) as a highly active immune stimulator that activates DCs via the cytoplasmic receptor known as STING (Stimulator of Interferon Genes), and compositions and uses thereof.
    Type: Application
    Filed: April 26, 2018
    Publication date: June 25, 2020
    Inventors: Justin LEONG, Chudi Obioma NDUBAKU, Jeffrey MCKENNA
  • LOCKED NUCLEIC ACID CYCLIC DINUCLEOTIDE COMPOUNDS AND USES THEREOF
    Publication number: 20190185511
    Abstract: The present invention provides highly active locked nucleic acid cyclic-dinucleotide (LNA-CDN) immune stimulators that activate DCs via the cytoplasmic receptor known as STING (Stimulator of Interferon Genes). In particular, the LNA-CDNs of the present invention are provided in the form of a composition comprising one or more cyclic dinucleotides that induce human STING-dependent type I interferon production, wherein the cyclic dinucleotides present in the composition have at least one 2?, 4? locked nucleic acids within the cyclic dinucleotide.
    Type: Application
    Filed: July 1, 2017
    Publication date: June 20, 2019
    Applicants: ADURO BIOTECH, INC., NOVARTIS AG
    Inventors: David Braun KANNE, Chudi Obioma NDUBAKU, Jacob Robert BRUML, Thanh Ngoc Lan LE, Jeffrey MCKENNA, George Scott TRIA, Stephen CANHAM
  • COMPOSITIONS AND METHODS FOR ACTIVATING "STIMULATOR OF INTERFERON GENE"-DEPENDENT SIGNALLING
    Publication number: 20190062365
    Abstract: The present invention provides highly active cyclic-di-nucleotide (CDN) immune stimulators that activate DCs via a recently discovered cytoplasmic receptor known as STING (Stimulator of Interferon Genes). In particular, the CDNs of the present invention are provided in the form of a composition comprising one or more cyclic purine dinucleotides induce human STING-dependent type I interferon production, wherein the cyclic purine dinucleotides present in the composition are 2?- or 3?-mono-fluoro substituted, or 2?3?-di-fluoro substituted mixed linkage 2?,5?-3?,5? CDNs.
    Type: Application
    Filed: October 28, 2016
    Publication date: February 28, 2019
    Applicants: ADURO BIOTECH, INC., NOVARTIS AG
    Inventors: George Edwin KATIBAH, David KANNE, Leonard SUNG, Kelsey GAUTHIER, Laura Hix GLICKMAN, Justin LEONG, Sarah M. McWHIRTER, Thomas W. DUBENSKY, Jr., Jeffrey McKENNA, Stephen M. CANHAM, Chudi Obioma NDUBAKU
  • Autotaxin inhibitors
    Patent number: 10183025
    Abstract: The present invention relates to novel compounds that are autotaxin inhibitors, processes for their preparation, pharmaceutical compositions and medicaments containing them and to their use in diseases and disorders mediated by autotaxin.
    Type: Grant
    Filed: August 9, 2017
    Date of Patent: January 22, 2019
    Assignee: Novartis AG
    Inventors: David Beattie, Urs Baettig, Darren Mark Le Grand, Andrew Stuart Lister, Jeffrey McKenna, David William Pearce, David Andrew Sandham, Oliver Ross Steward, Christopher Thomson
  • AUTOTAXIN INHIBITORS
    Publication number: 20180021345
    Abstract: The present invention relates to novel compounds that are autotaxin inhibitors, processes for their preparation, pharmaceutical compositions and medicaments containing them and to their use in diseases and disorders mediated by autotaxin.
    Type: Application
    Filed: August 9, 2017
    Publication date: January 25, 2018
    Applicant: Novartis AG
    Inventors: David BEATTIE, Urs BAETTIG, Darren Mark LE GRAND, Andrew Stuart LISTER, Jeffrey MCKENNA, David William PEARCE, David Andrew SANDHAM, Oliver Ross STEWARD, Christopher THOMSON
  • Autotaxin inhibitors
    Patent number: 9763957
    Abstract: The present invention relates to novel compounds that are autotaxin inhibitors, processes for their preparation, pharmaceutical compositions and medicaments containing them and to their use in diseases and disorders mediated by autotaxin.
    Type: Grant
    Filed: July 16, 2014
    Date of Patent: September 19, 2017
    Assignee: Novartis AG
    Inventors: David Beattie, Urs Baettig, Darren Mark Legrand, Andrew Stuart Lister, Jeffrey McKenna, David William Pearce, David Andrew Sandham, Oliver Ross Steward, Christopher Thomson
  • AUTOTAXIN INHIBITORS
    Publication number: 20160184318
    Abstract: The present invention relates to novel compounds that are autotaxin inhibitors, processes for their preparation, pharmaceutical compositions and medicaments containing them and to their use in diseases and disorders mediated by autotaxin.
    Type: Application
    Filed: July 16, 2014
    Publication date: June 30, 2016
    Applicant: Novartis AG
    Inventors: David BEATTIE, Urs BAETTIG, Darren Mark LEGRAND, Andrew Stuart LISTER, Jeffrey MCKENNA, David William PEARCE, Ddavid Andrew SANDHAM, Oliver Ross STEWARD, Christopher Thomson
  • AUTOTAXIN INHIBITORS
    Publication number: 20160168119
    Abstract: The present invention relates to novel compounds that are autotaxin inhibitors, processes for their preparation, pharmaceutical compositions and medicaments containing them and to their use in diseases and disorders mediated by autotaxin.
    Type: Application
    Filed: July 16, 2014
    Publication date: June 16, 2016
    Applicant: Novartis AG
    Inventors: Urs BAETTIG, David BEATTIE, Darren Mark LEGRAND, Andrew Stuart LISTER, Jeffrey MCKENNA, David William PEARCE, David Andrew SANDHAM, Emily STANLEY, Oliver Ross STEWARD, Christopher THOMSON
  • Tricyclic compounds for inhibiting the CFTR channel
    Patent number: 9359381
    Abstract: The present invention provides a compound of formula I or a pharmaceutically acceptable salt thereof; and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
    Type: Grant
    Filed: December 17, 2013
    Date of Patent: June 7, 2016
    Assignee: Novartis AG
    Inventors: Mahbub Ahmed, Alexander Ashall-Kelly, Louisa Gueritz, Jeffrey McKenna, Joseph McKenna, Simon Mutton, Rakesh Parmar, Jon Shepherd, Paul Wright
  • Substituted pyrazino[1?,2?:1,2]pyrrolo[3,4-d]pyrimidines, pyrimido[4?,5?:3,4]pyrrolo[2,1-c][1,4]oxazines and pyrimido[4?,5?:3,4]pyrrolo[1,2-d][1,4]oxazepines for inhibiting the CFTR channel
    Patent number: 9303035
    Abstract: The present invention provides a compound of formula I or a pharmaceutically acceptable salt thereof; and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
    Type: Grant
    Filed: December 17, 2013
    Date of Patent: April 5, 2016
    Assignee: Novartis AG
    Inventors: Mahbub Ahmed, Alexander Ashall-Kelly, Graham Charles Bloomfield, Louisa Gueritz, Jeffrey McKenna, Joseph McKenna, Simon Mutton, Rakesh Parmar, Jon Sheperd, Paul Wright
  • TRICYCLIC COMPOUNDS FOR INHIBITING THE CFTR CHANNEL
    Publication number: 20150336986
    Abstract: The present invention provides a compound of formula I or a pharmaceutically acceptable salt thereof; and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
    Type: Application
    Filed: December 17, 2013
    Publication date: November 26, 2015
    Applicant: Novartis AG
    Inventors: Mahbub AHMED, Alexander ASHALL-KELLY, Louisa GUERITZ, Jeffrey MCKENNA, Joseph MCKENNA, Simon MUTTON, Rakesh PARMAR, Jon SHEPHERD, Paul WRIGHT
  • TRICYCLIC COMPOUNDS
    Publication number: 20140171412
    Abstract: The present invention provides a compound of formula I or a pharmaceutically acceptable salt thereof; and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
    Type: Application
    Filed: December 17, 2013
    Publication date: June 19, 2014
    Applicant: NOVARTIS AG
    Inventors: Mahbub AHMED, Alexander ASHALL-KELLY, Graham Charles BLOOMFIELD, Louisa GUERITZ, Jeffrey MCKENNA, Joseph MCKENNA, Simon MUTTON, Rakesh PARMAR, Jon SHEPERD, Paul WRIGHT
  • TRICYCLIC COMPOUNDS
    Publication number: 20140171417
    Abstract: The present invention provides a compound of formula I or a pharmaceutically acceptable salt thereof; and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
    Type: Application
    Filed: December 17, 2013
    Publication date: June 19, 2014
    Applicant: NOVARTIS AG
    Inventors: Mahbub AHMED, Alexander ASHALL-KELLY, Louisa GUERITZ, Jeffrey MCKENNA, Joseph MCKENNA, Simon MUTTON, Rakesh PARMAR, Jon SHEPHERD, Paul WRIGHT
  • 3-Spirocyclic Piperidine Derivatives as Ghrelin Receptor Agonists
    Publication number: 20130331369
    Abstract: The invention relates to derivatives of formula (I), wherein the substituents are as defined in the specification; to processes for the preparation of such derivatives; pharmaceutical compositions comprising such derivatives; such derivatives as a medicament; such derivatives for the treatment of a disorder or a disease mediated by the ghrelin receptor.
    Type: Application
    Filed: August 8, 2013
    Publication date: December 12, 2013
    Applicant: Novartis AG
    Inventors: Ameet Vijay Ambarkhane, Gurdip Bhalay, Martin Beckett, James Dale, Ahmed Hamadi, Alessandro Mazzacani, Jeffrey McKenna, Christopher Thomson
  • 3-spirocyclic piperidine derivatives as ghrelin receptor agonists
    Patent number: 8546416
    Abstract: The invention relates to derivatives of formula (I), wherein the substituents are as defined in the specification; to processes for the preparation of such derivatives; pharmaceutical compositions comprising such derivatives; such derivatives as a medicament; such derivatives for the treatment of a disorder or a disease mediated by the ghrelin receptor.
    Type: Grant
    Filed: May 24, 2012
    Date of Patent: October 1, 2013
    Assignee: Novartis AG
    Inventors: Ameet Vijay Ambarkhane, Gurdip Bhalay, Martin Beckett, James Dale, Ahmed Hamadi, Alessandro Mazzacani, Jeffrey McKenna, Christopher Thomson